Gingivitis

A specifically designed randomized clinical trial (Nutrients, 2021) in adults with or at risk of metabolic syndrome found that 20 g/day of acacia gum for 12 weeks significantly reduced systolic and diastolic blood pressure, fasting plasma glucose, and improved bowel function. Acacia gum addresses multiple metabolic syndrome components simultaneously through its prebiotic, lipid-lowering, and glycemic-modulating properties.

Acai has been directly tested in humans with metabolic syndrome or metabolic syndrome risk factors in at least two controlled trials. Evidence shows improvements in oxidative and inflammatory markers, with modest lipid and glucose benefits in uncontrolled pilot data. A 2023 systematic and meta-analytic review found broad preclinical promise, while human trials remain limited.

Adzuki bean addresses multiple simultaneous features of metabolic syndrome—abdominal obesity, hyperglycemia, dyslipidemia, and hypertension—in animal models. A 2024 ResearchGate-cited review specifically discusses adzuki bean's progress in improving metabolic syndrome. Human evidence comes from the T2D RCT showing improvements in glycemic, lipid, and inflammatory markers.

The Maeda et al. (2005) RCT demonstrated simultaneous improvements in multiple metabolic syndrome components — body weight, BMI, fasting glucose, HbA1c, HOMA-IR, blood pressure, total cholesterol, and body fat — in obese patients with glucose dysregulation consuming agar over 12 weeks. This multi-component improvement profile directly addresses the clustering of metabolic syndrome features.

Akkermansia muciniphila, a mucin-degrading gut bacterium, has demonstrated clinically meaningful improvements across multiple components of metabolic syndrome—including insulin resistance, plasma cholesterol, body weight, and systemic inflammation—in human randomized controlled trials. Its abundance is inversely correlated with obesity, type 2 diabetes, and hypertension in epidemiological studies. Evidence is strongest for the pasteurized (heat-killed) form, which appears to outperform live bacteria in some metabolic endpoints. Current evidence, while promising, is still limited by small trial sizes and the absence of long-term outcome data.

ALA, a plant-derived essential omega-3 fatty acid, has been studied in clinical and epidemiological research for its effects on multiple components of metabolic syndrome (MetS), including dyslipidemia, hypertension, insulin resistance, and abdominal obesity. RCTs have demonstrated reductions in triglycerides, LDL cholesterol, and blood pressure with ALA supplementation. However, the overall evidence specifically for MetS as a composite outcome remains inconsistent, with two recent meta-analyses failing to find a significant association between ALA intake and MetS overall.

Alpha-Lipoic Acid (ALA) has substantive human clinical evidence supporting its use in metabolic syndrome (MetS), targeting multiple components: insulin resistance, dyslipidemia, inflammation, and central obesity. Multiple systematic reviews and meta-analyses of RCTs confirm significant reductions in key inflammatory markers (CRP, IL-6, TNF-α) and improvements in glycemic control and lipid profiles. Evidence strength is moderate-to-promising, though high-quality, large-scale trials specifically in MetS populations are still called for.

Omega-3 PUFAs including DHA from algal oil significantly improve key components of metabolic syndrome—including elevated triglycerides, high blood pressure, and dyslipidemia. A systematic review and meta-analysis of RCTs in metabolic syndrome patients found n-3 PUFAs significantly decreased serum triglycerides, systolic blood pressure, and diastolic blood pressure.

Almonds address multiple components of metabolic syndrome simultaneously—LDL cholesterol, fasting glucose, waist circumference, and diastolic blood pressure—making them a clinically studied dietary intervention for this cluster condition. A 2025 RCT specifically in adults with metabolic syndrome confirmed beneficial changes in cholesterol and intestinal inflammation biomarkers.

A 2025 MDPI retrospective observational study of a quince-olive leaf-amaranth nutraceutical (QUINOLAM) in 30 patients with metabolic syndrome showed significant reductions in total cholesterol, LDL-C, and fasting glycemia. Preclinical data showed enhanced LDL receptor expression and glucose uptake. Amaranth contributes multiple components relevant to metabolic syndrome: lipid-lowering, glucose-modulating, antioxidant, and blood pressure-reducing activities.

Low serum amylase activity is significantly and independently associated with metabolic syndrome in multiple human cohort studies. AMY1 copy number variation influences obesity, insulin resistance, and cardiometabolic risk factors. These associations are mechanistically linked to impaired starch digestion and downstream effects on glucose and lipid homeostasis.

EPA and DHA from anchovies have been studied in metabolic syndrome through multiple RCTs and meta-analyses. A 2023 PMC meta-analysis of 8 trials in metabolic syndrome patients found n-3 PUFAs significantly reduced triglycerides and both systolic and diastolic blood pressure, though effects on LDL-C, total cholesterol, and HDL were not significant.

Anemarrhena polysaccharides and mangiferin address multiple components of metabolic syndrome simultaneously in preclinical models: lowering blood glucose, reducing LDL and triglycerides, increasing HDL, and reducing inflammatory cytokines IL-6 and TNF-α.

A 24-week RCT in 82 adults with metabolic syndrome found annatto delta-tocotrienol combined with resveratrol improved all five MetS criteria including blood pressure, waist circumference, and triglycerides. A 2025 RCT using tocotrienol-enriched oats (annatto as tocotrienol source) also improved metabolic parameters in MetS patients. Traditional use of annatto for metabolic disorders is documented across Latin American healing systems.

Apple consumption and apple-derived polyphenols favorably affect multiple components of metabolic syndrome including dyslipidemia, blood pressure, fasting glucose, and abdominal obesity. Subgroup analyses in RCTs show strongest effects in individuals with baseline metabolic dysfunction.

ACV has been studied specifically for its effects on cardiometabolic syndrome (CMS), a cluster of metabolic risk factors. A meta-analysis of 25 clinical trials found it improved fasting glucose, HbA1c, and total cholesterol simultaneously. A 2026 PCOS RCT also assessed its adjunctive effects on metabolic syndrome components.

A 12-week preclinical study in glucose-fed rats showed argan oil prevented the full metabolic syndrome phenotype (hypertension, insulin resistance, dyslipidaemia, obesity). A human interventional study in metabolic syndrome patients showed improved dyslipidaemia with argan oil consumption.

Aronia melanocarpa extract has been studied directly in metabolic syndrome patients in prospective controlled trials, demonstrating reductions in blood pressure, blood glucose, lipid profile, platelet aggregation, and coagulation markers. One 4-week controlled trial found improvements across multiple MetS criteria simultaneously in confirmed MetS patients.

Artichoke has been specifically studied in metabolic syndrome populations across multiple RCTs. A 2025 meta-analysis of 21 RCTs (n=1,372) including metabolic syndrome participants found significant reductions in BMI, waist circumference, blood pressure, total cholesterol, LDL, and fasting blood glucose. A 6-month RCT in 100 metabolic syndrome patients found improvements in lipids, liver health, and carotid intima-media thickness.

Ashitaba has been specifically studied for metabolic syndrome. A pilot study in patients confirmed anti-obesity, hepatoprotective, antidiabetic, and antioxidant efficacy. Two small double-blind RCTs tested chalcone powder (200 mg/day) in overweight/metabolic syndrome adults over 8–12 weeks. Overall, ashitaba holds the most convergent human evidence for MetS.

A 2025 PMC literature review specifically on ashwagandha and metabolic syndrome confirmed it addresses multiple components: blood glucose, lipid profile, inflammation, and oxidative stress. Mechanisms include HMG-CoA reductase inhibition, PPAR-γ modulation, vasodilation, and antioxidant upregulation. Clinical evidence comes largely from trials in overweight/obese or diabetic populations.

Multiple randomized controlled trials (RCTs) and at least two systematic reviews/meta-analyses have directly investigated astaxanthin supplementation in adults with metabolic syndrome (MetS) risk factors. The strongest pooled finding is a significant reduction in LDL-cholesterol, with marginal effects on total cholesterol and systolic blood pressure. Combined with exercise, astaxanthin also improved body composition, lipid profiles, and insulin sensitivity. Evidence is real but still limited in scale, and individual study results remain inconsistent.

Banaba (Lagerstroemia speciosa L.) leaf extract has been directly studied in human clinical trials for Metabolic Syndrome (MetS). A 2022 randomized, double-blind, placebo-controlled trial in 24 IDF-diagnosed MetS patients found that 500 mg twice daily for 12 weeks produced statistically significant improvements in fasting glucose, insulin AUC, waist circumference, blood pressure, and triglycerides, with 67% of treated patients achieving MetS remission. Its primary bioactive compounds — corosolic acid and ellagitannins — act via multiple mechanisms relevant to all core features of MetS. Evidence is promising but limited by very small sample sizes.

Green banana products have shown clinical benefits across multiple components of metabolic syndrome including insulin resistance, body weight, blood pressure, and glycemia. The 2019 systematic review of 18 green banana clinical studies confirmed these benefits. Native banana starch improved insulin sensitivity and weight in obese diabetic subjects in controlled trials.

Multiple RCTs and a 2025 meta-analysis demonstrate that berberine/barberry significantly improves key metabolic syndrome components: TG, fasting glucose, waist circumference, LDL-C, and total cholesterol. A dedicated barberry RCT in 60 metabolic syndrome patients found significant reductions in systolic BP, TG, and cholesterol after 3 weeks.

Barley β-glucan addresses multiple components of metabolic syndrome: it lowers LDL cholesterol, reduces postprandial blood glucose and insulin, may reduce blood pressure, and decreases BMI and waist circumference. Human clinical trial evidence supports its use as a dietary strategy in metabolically at-risk populations.

The 2017 systematic review (24 trials) and 2018 meta-analysis of holy basil RCTs demonstrate simultaneous improvements in fasting glucose, lipid profiles (cholesterol, triglycerides), blood pressure, and insulin resistance—the core components of metabolic syndrome. The 2024 RCT (n=200) further supported multi-parameter metabolic benefits.

Bee pollen's phenolic and probiotic content has been shown to reduce fasting blood glucose, body weight gain, liver fat accumulation, and dyslipidemia in animal models — matching all major components of metabolic syndrome. A 2023 PMC scoping review specifically identifies metabolic disorders as a key translational target.

Beetroot addresses multiple components of metabolic syndrome simultaneously: blood pressure, insulin resistance, dyslipidemia, and oxidative stress. Human RCT data show individual benefits on these parameters, and one 8-week RCT in T2D patients showed improvements across several metabolic markers.

Multiple randomized controlled trials and meta-analyses provide clinical evidence that berberine meaningfully improves several core components of metabolic syndrome, including elevated triglycerides, fasting plasma glucose, and waist circumference. Its primary mechanism involves activation of AMP-activated protein kinase (AMPK), which improves insulin sensitivity and lipid metabolism. Evidence does not yet support syndrome-level remission, and effects on blood pressure and HDL-cholesterol are less consistent.

Berberis species are the primary botanical source of berberine, a quaternary isoquinoline alkaloid with well-documented clinical evidence across multiple components of metabolic syndrome. Multiple randomized controlled trials and meta-analyses confirm statistically significant reductions in triglycerides, fasting plasma glucose, waist circumference, LDL-C, and total cholesterol. Evidence is strongest for glycemic and lipid outcomes; effects on blood pressure and HDL-C are less consistent.

Beta-glucan, a soluble fiber from oats and barley, has well-documented clinical evidence supporting its role in addressing multiple components of metabolic syndrome (MetS), including dyslipidemia, impaired glucose metabolism, hypertension, and obesity. Both the FDA and EFSA have approved health claims for beta-glucan's LDL-cholesterol-lowering effect at ≥3 g/day. Multiple systematic reviews and RCTs confirm benefits across the core features of MetS, with the strongest evidence centered on lipid reduction and postprandial glycemic control.

Low plasma betaine concentrations are consistently reported in subjects with metabolic syndrome. Betaine's roles in homocysteine reduction, hepatic lipid metabolism, body composition, and blood sugar modulation all converge on metabolic syndrome features. Observational and cross-sectional human data support an inverse association between betaine status and metabolic syndrome risk.

Multiple human randomized controlled trials and systematic reviews demonstrate that Bifidobacterium species can beneficially modulate several components of metabolic syndrome, including body fat, fasting blood glucose, lipid profiles, and inflammatory markers. The primary proposed mechanisms involve restoring gut barrier integrity, reducing metabolic endotoxemia, and improving insulin sensitivity. Evidence is strain-specific, and effect sizes are modest; results across studies are not fully consistent.

B. animalis strains have been tested in RCTs in subjects with metabolic syndrome risk factors. A 12-week double-blind RCT of B. animalis TA-1 with L. paracasei MSMC39-1 in 58 participants with metabolic syndrome risk factors demonstrated significant reductions in LDL cholesterol, body weight, BMI, waist circumference, systolic blood pressure, and total cholesterol versus placebo. Effects are thought to be mediated through gut microbiota remodeling.

B. breve has been studied for individual components of metabolic syndrome — including body fat, triglycerides, cholesterol, blood glucose, and blood pressure — with favorable effects reported in multiple RCTs. B. breve B-3 reduced body fat mass, improved inflammatory markers, and showed modest improvements in lipid parameters in pre-obese adults. B. breve BBr60 significantly modulated metabolic pathways linked to cholesterol metabolism and glycolysis in an RCT in overweight/obese adults.

A randomized trial of B. lactis HN019 in 51 metabolic syndrome patients found significant reductions in BMI, total cholesterol, LDL, TNF-α, and IL-6 after 45 days. B. lactis strains thus address multiple components of MetS—dyslipidemia, inflammation, and central obesity—simultaneously.

Bilberry supplementation has been studied across multiple components of metabolic syndrome including hyperglycemia, dyslipidemia, hypertension, inflammation, and oxidative stress. A systematic review found bilberry/blackcurrant improved HbA1c and cholesterol in subjects with metabolic syndrome. Its anthocyanins address several simultaneous metabolic syndrome risk factors.

Bile acid signaling through FXR and TGR5 regulates multiple components of metabolic syndrome including dyslipidemia, insulin resistance, obesity, and hepatic fat accumulation. Human studies show bile acid metabolism is altered in metabolic syndrome, and modulation via FXR agonists, TGR5 agonists, and bile acid sequestrants are active therapeutic strategies. Colesevelam is FDA-approved for both hypercholesterolemia and T2DM, addressing two cardinal features of metabolic syndrome.

Multiple RCTs and the 2025 meta-analysis of 82 RCTs confirm N. sativa improves all core components of metabolic syndrome—blood pressure, dyslipidaemia, hyperglycaemia, and obesity. An RCT in 60 metabolic syndrome patients showed NS oil with standard medications significantly reduced FBS, LDL, and total cholesterol.

Multiple RCTs specifically conducted in metabolic syndrome populations show blueberries reduce inflammatory markers, improve endothelial function, and modestly improve some glycemic and lipid parameters. A systematic review found six human intervention trials using blueberry in MetS subjects.

A systematic review and meta-analysis of 10 clinical trials found that broccoli sprout supplementation significantly reduced blood pressure and produced marginally significant improvements in lipid biomarkers — both core components of metabolic syndrome. Most trials enrolled participants with metabolic syndrome-related conditions including T2D, hypertension, and fatty liver.

Glucosinolate-derived isothiocyanates and indoles from Brussels sprouts address multiple components of metabolic syndrome — including hyperglycemia, dyslipidemia, hypertension, and systemic inflammation — through NF-κB inhibition, Nrf2 activation, and improvements in insulin signaling. A dedicated PMC review (2020) specifically analyzed cruciferous glucosinolate derivatives in the context of metabolic syndrome.

Butyrate addresses multiple components of metabolic syndrome, including adipose tissue inflammation, glucose dysregulation, and dyslipidemia. A human RCT in patients with liver steatosis and metabolic syndrome using a calcium butyrate formula showed improved fatty liver index and lipid parameters. A sodium butyrate study at 4 g/day for 4 weeks failed to show benefit in metabolic syndrome patients, illustrating inconsistent results. Tributyrin animal data show adipose inflammation reduction and improved insulin responsiveness.

Clinical evidence shows that butyrate supplementation influences multiple components of metabolic syndrome including blood pressure, blood sugar, HbA1c, triglycerides, and cholesterol. Results are inconsistent across trials, with some showing benefit and others finding no significant effect.

In metabolic syndrome, plasma campesterol levels and the campesterol:cholesterol ratio are characteristically reduced compared to healthy controls, reflecting the predominance of cholesterol synthesis over absorption in this condition. This altered campesterol profile is used as a metabolic marker. Phytosterol supplementation addresses key components of metabolic syndrome including dyslipidemia.

The 2024 human RCT (Cell Reports Medicine) specifically enrolled overweight, hypertriglyceridemic adults — a population with metabolic syndrome features — and measured anthropometric indices, plasma lipids, blood pressure, and glucose homeostasis as secondary outcomes alongside hepatic steatosis. ACS Omega review identifies metabolic syndrome–related diseases (type 2 diabetes, cardiovascular disease) as key targets of camu camu biofunctional compounds.

Capsaicinoids have been specifically studied for modulating metabolic syndrome risk factors including abdominal adiposity, blood glucose, blood pressure, lipid profile, and endothelial function. A dedicated 2016 review in the Journal of Nutrition and Metabolism summarizes convergent evidence across these domains.

Capsanthin addresses multiple components of metabolic syndrome in preclinical models: reducing weight gain, lowering triglycerides and LDL-C, raising HDL-C, improving glucose tolerance, reducing TMAO, and modulating gut microbiota diversity. Evidence is entirely preclinical.

Multiple systematic reviews and meta-analyses of RCTs specifically in metabolic syndrome patients confirm that capsaicin supplementation significantly reduces total cholesterol and LDL-C, with supporting data on glucose and blood pressure. Capsaicin targets several MetS components simultaneously via TRPV1-mediated metabolic pathway activation.

Cardamom has been studied specifically in populations with metabolic syndrome and its components (insulin resistance, hypertension, dyslipidemia, abdominal obesity, and systemic inflammation). A 2021 narrative review in PMC surveyed in vivo, in vitro, and clinical studies, finding broad-spectrum activity across MetS parameters. Clinical trials consistently show improvements in triglycerides, blood pressure, and inflammatory markers.

BCP improved multiple components of metabolic syndrome in rodent models including dyslipidemia, insulin resistance, visceral inflammation, and vascular dysfunction via CB2 and PPAR-γ pathways. It outperformed pioglitazone on some anti-inflammatory measures.

C. cassia addresses multiple components of metabolic syndrome simultaneously—fasting blood glucose, insulin resistance, triglycerides, cholesterol, and body weight—making it relevant to the syndrome as a composite entity. Clinical trial evidence supports effects on individual components in T2DM populations, and a 2020 comparative review included metabolically related conditions as part of its scope.

Catechins target multiple components of metabolic syndrome simultaneously—abdominal obesity, hyperglycemia, dyslipidemia, hypertension, and low-grade inflammation. Clinical trials in metabolic syndrome patients consistently show improvements in waist circumference, triglycerides, blood pressure, fasting glucose, and inflammatory markers.

Capsaicin has been specifically evaluated as a multitarget intervention for metabolic syndrome, addressing central obesity, insulin resistance, dyslipidaemia, hypertension, and chronic low-grade inflammation. A 2022 PMC review and a meta-analysis of RCTs in metabolic syndrome patients both document meaningful effects on lipid profiles and cardiometabolic risk factors.

A 2025 RCT (NCT06061926) in 28 metabolic syndrome patients found 75 mg celery seed twice daily for 12 weeks significantly reduced SBP, DBP, triglycerides, VLDL, and uric acid. A PubMed 2019 review summarized celery's hypolipidemic, antidiabetic, and hypotensive properties relevant to MetS.

Chen Pi's PMFs and hesperidin simultaneously target the core components of metabolic syndrome—elevated lipids, blood glucose, inflammation, and endothelial dysfunction—in human and animal studies. A hesperidin RCT specifically in metabolic syndrome patients demonstrated improved endothelial function and reduced blood pressure.

Chia seeds address multiple components of metabolic syndrome simultaneously: hypertension, dyslipidemia, blood glucose dysregulation, overweight, and inflammation. A 2025 narrative review in Plant Foods for Human Nutrition specifically addresses chia's role in managing metabolic syndrome and its risk conditions.

Chickpea protein and whole chickpeas address multiple components of metabolic syndrome simultaneously, including elevated blood glucose, dyslipidaemia, and inflammation. A high-fat-diet murine study with chickpea protein hydrolysate demonstrated amelioration of obesity-induced metabolic markers. Human clinical trials show concurrent improvements in cholesterol, glycaemia, and CRP in at-risk populations.

Chicory inulin-type fructans address multiple components of metabolic syndrome — elevated blood glucose, dyslipidemia, excess adiposity, and elevated blood pressure — in clinical trials. Effects are most consistent and statistically significant in subjects with diabetes or obesity, which commonly underlie metabolic syndrome diagnosis.

Danshen has been used for over 2,000 years in the clinical treatment of NAFLD and metabolic syndrome. Its active compounds improve lipid metabolism, reduce hepatic steatosis, lower blood viscosity, and protect the vasculature—all core components of metabolic syndrome. Clinical evidence comes primarily from liver disease and dyslipidemia trials.

A systematic review of RCTs on Chlorella vulgaris and obesity-related metabolic disorders found evidence supporting improvements in dyslipidemia, hyperglycemia, and blood pressure—all components of metabolic syndrome. Effects on BMI and waist circumference were less consistent.

Several prospective clinical trials specifically in metabolic syndrome patients show chokeberry extract simultaneously reduces blood pressure, fasting blood glucose, total cholesterol, LDL-C, and coagulation risk within 4–8 weeks. These are among the most directly applicable human studies and represent the strongest single-disease evidence base for chokeberry.

Chromium supplementation has been studied in metabolic syndrome given that insulin resistance is a shared feature. A prospective cohort study found lower toenail chromium concentrations were associated with higher incidence of metabolic syndrome. However, a controlled trial in 65 metabolic syndrome patients found no benefit on glucose, insulin, or lipid parameters, and both the NIH ODS and Linus Pauling Institute conclude current evidence does not support chromium for treating metabolic syndrome.

Chromium has been clinically investigated for metabolic syndrome due to its proposed role in enhancing insulin signaling, but evidence for benefit specifically in metabolic syndrome patients is weak and inconsistent. The NIH Office of Dietary Supplements and the Linus Pauling Institute both conclude that current research does not demonstrate meaningful benefit for metabolic syndrome. A 2025 RCT in MetS patients found modest improvements in HbA1c, HDL-C, and blood pressure with chromium picolinate, though clinical significance was uncertain. The overall picture is one of mixed results, with chromium performing more favorably in overt type 2 diabetes with elevated baseline glucose than in metabolic syndrome per se.

Chrysin and its formulations address multiple components of metabolic syndrome in animal models, including hyperglycemia, dyslipidemia, insulin resistance, and hepatic steatosis. The ACS JAFC 2021 study specifically used metabolic syndrome as a model, demonstrating improvements across glucose and lipid parameters via AMPK/PI3K/AKT. Evidence is preclinical.

Multiple randomized controlled trials and meta-analyses demonstrate that cinnamon supplementation significantly improves fasting blood glucose, insulin sensitivity, and lipid profiles in individuals with metabolic syndrome. An umbrella review of 21 meta-analyses (2025, PMC) confirms these effects, with more pronounced benefits at doses above 1.5 g/day. Evidence quality is graded as moderate-to-weak, and further large, long-duration RCTs are still needed to solidify clinical recommendations.

CQ is one of the most-studied herbal interventions for metabolic syndrome, with multiple randomized, double-blind, placebo-controlled trials showing simultaneous improvements in body weight, fasting blood glucose, total cholesterol, LDL, triglycerides, and CRP. The primary human evidence comes from Oben et al. (2006, 2007) and a 2012 RCT using CQR-300.

C. sinensis hesperidin has been tested in subjects with metabolic syndrome in RCTs, showing improvements in endothelial function, blood pressure, and lipid biomarkers. A Springer review of Citrus species against metabolic syndrome confirms multiple preclinical and clinical study data points. Flavanone-rich interventions address multiple MetSyn components simultaneously.

CLA has been evaluated in metabolic syndrome patients via systematic review and meta-analysis. RCTs show modest but significant reductions in body weight and BMI in this population. However, CLA also adversely reduced HDL cholesterol and showed no benefit on blood pressure, insulin resistance, or triglycerides.

A 2025 systematic review and meta-analysis specifically in individuals with metabolic syndrome found cocoa supplementation significantly lowered triglycerides and blood pressure. Cocoa flavanols address multiple components of metabolic syndrome simultaneously, including blood pressure, glucose, and lipids. Evidence is strongest for BP and triglycerides in this population.

Omega-3 fatty acids from cod liver oil address multiple metabolic syndrome components: triglycerides, blood pressure, insulin resistance, and inflammation. A meta-analysis of 8 RCTs found omega-3 supplementation significantly reduced triglycerides and systolic and diastolic blood pressure in metabolic syndrome patients.

An RCT in metabolic syndrome patients (British Journal of Nutrition, 2018) found green coffee extract significantly attenuated fasting blood sugar versus placebo. Coffee polyphenols are inversely associated with metabolic syndrome risk in epidemiological data. CGA addresses multiple components of metabolic syndrome: blood pressure, triglycerides, blood sugar, and weight.

Coix seed extracts improve multiple metabolic syndrome components simultaneously in animal models—reducing body weight, blood glucose, total cholesterol, triglycerides, and LDL-C, while improving HDL-C and gut microbiota. This positions coix as a multi-target metabolic agent.

A 12-week double-blind RCT demonstrated that Coleus forskohlii extract combined with a hypocaloric diet significantly reduced multiple metabolic syndrome risk factors—including insulin resistance and waist/hip circumference—compared to placebo in overweight/obese adults. HDL-C also improved.

Berberine from Coptis chinensis addresses multiple components of metabolic syndrome including insulin resistance, hyperglycemia, dyslipidemia, and obesity, as demonstrated in RCTs and meta-analyses. Coptis is recognized as a primary TCM herb for metabolic syndrome in the Chinese medical literature.

Multiple randomized controlled trials (RCTs) and meta-analyses demonstrate that CoQ10 supplementation can beneficially modulate key features of metabolic syndrome (MetS), including oxidative stress, inflammation, insulin resistance, and adipokine dysregulation. A 2020 PMC meta-analysis of RCTs (318 participants) found CoQ10 significantly increased adiponectin and lowered inflammation markers in MetS patients. However, effects on individual components such as dyslipidemia, hypertension, and glycemia are inconsistent across trials, and at least one RCT found no significant benefit of CoQ10 alone on MetS components.

Corn silk extract addresses multiple components of metabolic syndrome simultaneously in preclinical studies, including hyperglycemia, dyslipidemia, hypertension, and excess body weight. A 2019 meta-analysis of RCTs confirmed blood pressure reduction when corn silk tea was added to antihypertensive therapy. Lipid and glucose effects are confirmed in animal models.

Several RCTs have specifically enrolled subjects with metabolic syndrome and found that cranberry consumption can improve antioxidant capacity, lipid peroxidation, and certain cardiometabolic biomarkers. Benefits on glycemic control, lipids, and blood pressure are modest and inconsistent. The evidence base includes dedicated trials in this population alongside mechanistic preclinical data.

Epidemiological studies consistently show inverse associations between serum BCX and metabolic syndrome prevalence. BCX regulates NF-κB and Nrf2 pathways implicated in MetS, and reduces dyslipidemia, insulin resistance, and inflammatory markers in animal models. A C. elegans transcriptomic study supports metabolic syndrome pathway modulation.

A 2025 GRADE-assessed meta-analysis of 9 RCTs found cumin significantly improved multiple metabolic syndrome components: fasting blood sugar, triglycerides, HDL-cholesterol, and waist circumference. Evidence quality was rated low to moderate due to heterogeneity.

Curcumin, the principal bioactive polyphenol of Curcuma longa, has been investigated in multiple randomized controlled trials (RCTs) and several meta-analyses specifically in patients with metabolic syndrome (MetS). Clinical evidence shows it can favorably affect blood glucose, lipid levels, blood pressure, waist circumference, inflammatory markers, and insulin sensitivity. Results across trials are heterogeneous, and more high-quality RCTs are still needed to firmly establish optimal dosing and mechanisms.

D-alpha tocopherol has been studied in metabolic syndrome through its role in NAFLD/NASH, insulin resistance, and oxidative stress. Clinical data from NAFLD trials demonstrate improvements in liver enzymes and hepatic lipid metabolism, which are central to the metabolic syndrome phenotype.

Daidzin and daidzein address multiple components of metabolic syndrome simultaneously in animal models: blood glucose, triglycerides, obesity, and inflammation. A 92-day daidzin/glycitin mouse study showed reductions in body weight, adipose tissue, blood glucose, HbA1c, and oxidative stress markers.

A 2022 PMC narrative review (PMC9498421) specifically examined dandelion as a source of bioactive compounds supporting treatment of co-existing diseases in metabolic syndrome, covering its effects on blood glucose, lipids, blood pressure, and inflammation. Preclinical evidence addresses multiple MetS components. Human trial data remain scarce.

DHA (docosahexaenoic acid), a marine-derived long-chain omega-3 fatty acid, has well-documented clinical evidence supporting its role in addressing key components of metabolic syndrome, most robustly hypertriglyceridemia. Multiple systematic reviews and meta-analyses of RCTs confirm significant triglyceride-lowering effects, with more modest or inconsistent effects on blood pressure, insulin resistance, and other MetS markers. The evidence base is clinical and mechanistic, not traditional.

Low DHEAS levels have been associated with components of metabolic syndrome including insulin resistance, visceral obesity, and dyslipidemia. DHEA supplementation studies show modest reductions in fat mass and some improvements in triglycerides and glucose tolerance in select populations. Overall evidence for reversing metabolic syndrome is mixed and not sufficient to support routine use.

Dioscorea dioscorin and polysaccharides have shown improvements in metabolic syndrome parameters—including blood glucose, lipids, and adiposity—in obese rodent models. The evidence base is preclinical, with no human trials. A 2022 systematic review flagged metabolic syndrome as a key target area.

DHA addresses multiple components of metabolic syndrome simultaneously: it lowers triglycerides, raises HDL cholesterol, reduces blood pressure, decreases oxidative stress, and has anti-inflammatory effects. A USDA RCT in hypertriglyceridemic men found DHA supplementation improved fasting and postprandial lipid profiles relevant to metabolic syndrome.

Clinical evidence links Rosa canina intake to improvement of multiple metabolic syndrome components simultaneously, including visceral fat reduction, LDL cholesterol lowering, systolic blood pressure reduction, and fasting glucose improvement. A dedicated RCT in pre-obese subjects found significant abdominal visceral fat reduction, and a systematic review confirmed cardiometabolic risk factor improvement.

DPA has been associated with improvement in multiple metabolic syndrome components including elevated triglycerides, impaired insulin sensitivity, and dyslipidemia in animal and human observational data. DPA levels are inversely correlated with CRP and triglycerides in humans, two core features of metabolic syndrome. Mechanistic evidence includes GPR120 and PPARγ activation.

EGCG (Epigallocatechin Gallate), the primary bioactive polyphenol in green tea, has been investigated in multiple human randomized controlled trials (RCTs) and systematic reviews for its effects on metabolic syndrome components, including dyslipidemia, insulin resistance, hypertension, and visceral adiposity. Clinical evidence shows modest but meaningful improvements in triglycerides, LDL cholesterol, blood pressure, and inflammatory markers, particularly with doses of 150–800 mg/day over 8–16 weeks. Results are mixed across trials, with some parameters (e.g., HbA1c, fasting insulin) showing only modest or non-significant effects. Overall, the evidence base is scientific but not yet conclusive enough to support EGCG as a standalone intervention for metabolic syndrome.

EPA addresses multiple components of metabolic syndrome simultaneously: significantly lowering triglycerides, improving HDL-C, reducing adipose inflammation, and modestly improving insulin sensitivity in overweight populations. EPA-predominant omega-3 formulations showed 25% reductions in cardiovascular events in metabolic syndrome patients in the REDUCE-IT trial.

E. littorale and swertiamarin address multiple components of metabolic syndrome simultaneously: hyperglycaemia, dyslipidaemia, insulin resistance, hypertension, and obesity—all demonstrated in preclinical models and partially in a human diabetic cohort. The PPAR-γ-targeting mechanism of swertiamarin is particularly relevant to metabolic syndrome pathophysiology.

EPA, a marine-derived omega-3 polyunsaturated fatty acid, has robust clinical evidence supporting its role in addressing key components of metabolic syndrome (MetS), most notably hypertriglyceridemia. Multiple systematic reviews and meta-analyses of RCTs confirm that EPA significantly reduces serum triglycerides, and also favorably affects total cholesterol and LDL-C. Evidence for improvements in insulin resistance and blood pressure is present but more modest and context-dependent. EPA and DHA show distinct lipid effects, with EPA being preferable for patients where LDL-C elevation is a concern.

Eucommia leaf extract addresses multiple components of metabolic syndrome simultaneously in animal models: reducing body weight, visceral fat, blood pressure, plasma triglycerides, insulin resistance, and inflammatory adipokines. This multi-target action is consistent with published reviews describing eucommia's effects on hypertension, obesity, hyperglycemia, and dyslipidemia.

Multiple randomized controlled trials and a 2022 dose-response meta-analysis of 29 RCTs demonstrate that fenugreek supplementation significantly improves the core components of metabolic syndrome (MetS), including fasting plasma glucose, triglycerides, HDL-cholesterol, waist circumference, and systolic blood pressure. Effects on BMI and diastolic blood pressure were not significant. The bioactive compounds diosgenin, 4-hydroxyisoleucine (4-OHIle), and soluble galactomannan fiber are the primary mediators of these metabolic effects. Evidence quality is moderate, with notable heterogeneity across trials warranting cautious interpretation.

Ferulic acid addresses all major components of metabolic syndrome: it lowers LDL-C, total cholesterol, and triglycerides; raises HDL-C; reduces blood pressure via NO/oxidative stress mechanisms; improves insulin sensitivity; and reduces systemic inflammation. The 2018 human RCT in hyperlipidemic subjects provides direct evidence across multiple MetS parameters simultaneously. A 2025 MDPI review confirms FA as a promising nutraceutical for MetS management.

Fisetin alleviates multiple components of metabolic syndrome—including hyperglycemia, dyslipidemia, obesity, and cardiac insulin resistance—in HFD and diabetic rodent models. It is explicitly described as having 'potential activities to alleviate obesity-induced metabolic syndrome' in peer-reviewed literature.

Fish oil, via its EPA and DHA content, has substantial clinical and epidemiological evidence supporting a role in addressing key components of metabolic syndrome (MetS), particularly elevated triglycerides and high blood pressure. Multiple RCTs and meta-analyses confirm significant triglyceride-lowering and modest antihypertensive effects in MetS patients. Effects on HDL cholesterol, fasting glucose, and waist circumference are less consistent. Overall evidence is graded as clinically meaningful but not uniformly positive across all MetS criteria.

Multiple randomized controlled trials and systematic reviews demonstrate that flaxseed supplementation meaningfully improves several components of metabolic syndrome, including elevated triglycerides, insulin resistance, blood pressure, and central obesity. Whole or ground flaxseed (typically 30 g/day) consistently outperforms lifestyle modification alone across these markers. The evidence base is clinical, not merely traditional, though study sizes remain modest and heterogeneity across trials is high.

A 12-week RCT specifically evaluated C. forskohlii extract in overweight/obese subjects for metabolic syndrome risk factors, finding improvements in insulin resistance and HDL-cholesterol. Reductions in body fat and blood pressure have been noted across multiple trials.

ITF including FOS have been studied for multiple features of metabolic syndrome (obesity, dyslipidemia, hyperglycemia), with human RCT evidence strongest for blood glucose and cholesterol lowering in diabetic subjects. Benefits across the full metabolic syndrome cluster are inconsistent in non-diabetic populations, and no large RCT has specifically targeted metabolic syndrome as a primary endpoint.

Gamma oryzanol targets multiple components of metabolic syndrome—dyslipidemia, insulin resistance, obesity-related inflammation, and hyperglycemia—through several molecular pathways. Animal studies demonstrate protective effects against the full metabolic syndrome phenotype. A 2025 clinical review identifies emerging human evidence for its utility.

A dedicated 16-week double-blind RCT in 84 patients with type 2 diabetes and metabolic syndrome tested Ganoderma lucidum for metabolic syndrome risk factors. A 2025 meta-analysis of 17 RCTs found significant BMI reduction. Preclinical data on lipid, glucose, and inflammatory components of metabolic syndrome are extensive.

Garbanzo beans simultaneously address multiple components of metabolic syndrome—elevated blood glucose, dyslipidemia (high triglycerides, low HDL, high LDL), blood pressure, and abdominal obesity—through their fiber, protein, phytosterol, and bioactive peptide content. Meta-analyses of dietary pulses (Sievenpiper et al. series, ClinicalTrials NCT01594567) include metabolic syndrome as a primary studied condition with favorable outcomes across cardiometabolic risk factors.

Gardenia jasminoides extract addresses multiple components of metabolic syndrome—including hyperglycemia, insulin resistance, dyslipidemia, hypertension, and hepatic steatosis—in rodent models. A 2024 PMC study showed GJ extract attenuated high-fat-diet-induced glycolipid metabolism disorder by targeting gut microbiota and TLR4/Myd88/NF-κB pathway.

Gardenia jasminoides and its constituents have been studied in high-fat diet rodent models of metabolic syndrome, demonstrating effects on blood glucose, blood lipids (triglycerides, cholesterol), and gut microbiota remodeling. A 2024 PMC study demonstrated attenuation of glycolipid metabolism disorder in HFD rats via gut microbiota targeting and TLR4/Myd88/NF-κB pathway. Evidence is preclinical.

Multiple systematic reviews and meta-analyses of randomized controlled trials (RCTs) confirm that garlic supplementation significantly improves several core components of metabolic syndrome (MetS), including blood pressure, lipids, fasting glucose, waist circumference, and BMI. The primary bioactive compounds — allicin and related organosulfur molecules — act through vasodilation, antioxidant, lipid-regulatory, and insulin-sensitizing mechanisms. Evidence is clinically meaningful but tempered by high heterogeneity across trials and the need for larger, standardized studies.

Garlic simultaneously addresses multiple components of metabolic syndrome: hypertension, dyslipidemia, hyperglycemia, insulin resistance, and excess adiposity. Multiple RCTs and meta-analyses confirm garlic's effects on each individual component. A garlic powder RCT in NAFLD patients showed significant improvements in waist circumference, body fat, fasting glucose, and insulin resistance.

Genistein supplementation has been specifically studied in postmenopausal women with metabolic syndrome, where it produced significant improvements in LDL-C, total cholesterol, triglycerides, blood pressure, and insulin resistance markers. A meta-analysis confirmed these lipid-lowering effects are most pronounced in this subgroup. Multiple clinical trials also show reductions in fasting glucose and HOMA-IR in metabolic syndrome populations.

Multiple randomized controlled trials and meta-analyses demonstrate that ginger (Zingiber officinale) significantly improves key components of metabolic syndrome, including fasting blood glucose, HbA1c, insulin resistance (HOMA-IR), and lipid profiles. A 2018 meta-analysis of 10 RCTs (490 individuals) found ginger produced a pooled HbA1c reduction of −1.00 (95% CI: −1.56, −0.44; P < 0.001). A dedicated RCT in MetS patients using 2 g/day for 12 weeks showed significant improvements in triglycerides, fasting blood glucose, and insulin resistance versus placebo. Evidence is consistent across glycemic and lipid endpoints, though effects on blood pressure and BMI are less robust.

Multiple human clinical trials and systematic reviews support ginseng—particularly Korean Red Ginseng (KRG)—as beneficial across several components of metabolic syndrome, including hyperglycemia, dyslipidemia, hypertension, and obesity. An umbrella review (Frontiers in Pharmacology, 2023) found moderate-quality evidence that ginseng reduces total cholesterol, triglycerides, and LDL-C in metabolic syndrome patients versus placebo. A 2021 PMC-indexed review (Food Science & Nutrition) concluded that ginseng can control metabolic syndrome via antihyperglycemic, antihyperlipidemic, antihypertensive, and anti-obesity mechanisms. Overall evidence quality is moderate at best, and larger, longer-duration RCTs are still needed.

GLA has been used for metabolic syndrome (Syndrome-X) based on its documented effects on multiple metabolic syndrome components: triglycerides, HDL-cholesterol, LDL-cholesterol, and blood pressure. Clinical reference sources list metabolic syndrome as a recognized indication for GLA, and its lipid and anti-inflammatory effects are mechanistically relevant.

Glucomannan addresses several components of metabolic syndrome simultaneously — elevated fasting glucose, dyslipidemia (high LDL, high triglycerides), and body weight — as confirmed in meta-analyses and RCTs. A controlled metabolic trial (Vuksan 2000, Diabetes Care) in subjects with insulin resistance syndrome showed significant improvements in multiple MetS-related markers.

Plasma glycine levels are lower in subjects with metabolic syndrome than in healthy individuals. A published clinical trial (Díaz-Flores et al., 2013) found oral glycine supplementation reduced oxidative stress and improved systolic blood pressure in metabolic syndrome patients. Reviews in PubMed support a role for glycine in addressing multiple metabolic syndrome components including dyslipidemia, hyperglycemia, and hypertension.

A clinical study specifically in metabolic syndrome patients found that 14 g/day dried goji berry for 45 days significantly reduced abdominal waist circumference, LDL cholesterol, and lipid peroxidation while increasing antioxidant capacity. Reviews identify goji berry as a promising nutraceutical for managing the cluster of metabolic dysfunction. Multiple bioactive mechanisms—antioxidant, anti-inflammatory, glycemic, and lipid-modulating—are relevant.

A double-blind, placebo-controlled RCT specifically in metabolic syndrome patients (Usharani et al., 2019, BMC Complementary and Alternative Medicine) demonstrated that standardized amla extract improved endothelial dysfunction, oxidative stress, systemic inflammation, and lipid profiles. A separate trial in obese adults found reductions in visceral fat, BMI, and waist circumference.

GSE has been directly studied in metabolic syndrome populations in RCTs targeting insulin resistance, blood pressure, dyslipidemia, and body composition. A clinical trial tested 300 mg/day GSE in metabolic syndrome subjects for insulin resistance, oxidized LDL, and oxidative stress. A 2020 Iranian RCT studied 8-week GSE supplementation in adolescents with MetS. GSE addresses multiple MetS components simultaneously via proanthocyanidin-mediated effects.

GSE has been studied specifically in metabolic syndrome populations, demonstrating improvements in multiple components: insulin resistance, blood pressure, LDL cholesterol, and inflammatory markers (hsCRP). An RCT in adolescents with metabolic syndrome found GSE improved insulin resistance. Reviews of 20 GSE studies confirmed benefits in subjects with metabolic syndrome.

Grapefruit and its flavonoids (naringin, naringenin) address multiple components of metabolic syndrome simultaneously, including elevated blood pressure, dyslipidemia, abdominal obesity, and insulin resistance. RCT subgroup analyses and epidemiological data specifically in metabolic syndrome patients show greater benefits than in the general population. Naringin supplementation is cited in multiple reviews as beneficial for metabolic syndrome management.

Green tea, principally via its catechin epigallocatechin-3-gallate (EGCG), has been investigated in multiple RCTs and meta-analyses for its effects on the core components of metabolic syndrome—obesity, dyslipidemia, hyperglycemia, and elevated blood pressure. Evidence suggests modest benefits on body weight, BMI, waist circumference, and LDL cholesterol, though the most recent PRISMA-guided meta-analyses focusing specifically on diagnosed MetS patients found no statistically significant pooled effect on fasting glucose, HbA1c, blood pressure, or lipid fractions, with high inter-study heterogeneity. Inflammatory benefits are similarly mixed: green tea significantly reduced TNF-α but not CRP or IL-6 in a 2024 PMC meta-analysis of 15 RCTs.

The landmark Krewer et al. (2011, Phytotherapy Research) epidemiological study of an elderly Amazonian population found the prevalence of metabolic syndrome was significantly lower in habitual guarana consumers compared to non-consumers. This was accompanied by lower rates of obesity, hypertension, and improved lipid and oxidative biomarkers. Animal models support guarana's anti-obesity and lipid-correcting effects.

Guggulsterones, the active ketosteroids from Commiphora mukul resin, have documented traditional Ayurvedic use and laboratory/clinical investigation for key components of metabolic syndrome—dyslipidemia, insulin resistance, obesity, and inflammation. Mechanistically, they antagonize the farnesoid X receptor (FXR) and modulate PPARγ, LXR, and NF-κB pathways relevant to lipid and glucose homeostasis. Human clinical evidence is mixed: earlier Indian trials suggested lipid benefits, but a well-designed 2003 JAMA RCT found guggulipid did not lower cholesterol and may raise LDL in Western populations. A 2015 human pilot in 78 metabolic syndrome patients using a multi-ingredient formula containing guggul showed metabolic improvements, though guggulsterone's isolated contribution remains unclear.

Gymnema sylvestre has direct human clinical evidence relevant to metabolic syndrome (MetS), targeting its core components: elevated blood glucose, dyslipidemia, excess body weight, and blood pressure. A 2017 randomized double-blind placebo-controlled trial in MetS patients found significant reductions in body weight, BMI, and VLDL after 12 weeks of supplementation. A 2022 systematic review and meta-analysis further confirmed significant decreases in triglycerides, total cholesterol, LDL, fasting blood sugar, and diastolic blood pressure across multiple trials. Evidence is promising but currently limited by small sample sizes and study heterogeneity.

Gymnema sylvestre has direct human clinical evidence supporting its use in Metabolic Syndrome (MetS). A randomized, double-blind, placebo-controlled trial in 24 MetS patients tested 600 mg/day for 12 weeks, evaluating all canonical MetS components plus insulin sensitivity and secretion. A 2021 meta-analysis of 10 studies (419 patients) further confirmed significant reductions in fasting blood glucose, postprandial glucose, HbA1c, triglycerides, and total cholesterol. Evidence quality is moderate; trials are small and some lack rigor.

Hawthorn, particularly C. pinnatifida, has been reviewed for its effects on metabolic syndrome components including dyslipidemia, hyperglycemia, hypertension, and elevated inflammatory markers. Combined animal and limited clinical data support improvements across multiple MetS parameters simultaneously through AMPK, PPAR, and antioxidant pathways.

Hesperidin (metabolized to hesperetin) has shown positive effects on multiple components of metabolic syndrome including dyslipidemia, hypertension, and insulin resistance in human studies. A meta-analysis of RCTs confirmed improvements in TG, TC, LDL, and SBP, all core features of metabolic syndrome.

Hesperidin has been directly studied in patients with metabolic syndrome (MetS) in at least one double-blind RCT and is mechanistically positioned to address multiple MetS components including dyslipidemia, hyperglycemia, inflammation, and elevated blood pressure. Preclinical and emerging clinical studies support its role in MetS management.

Hibiscus sabdariffa (roselle) has been investigated in multiple human clinical trials for its effects on all core components of metabolic syndrome—hypertension, dyslipidemia, hyperglycemia, and abdominal obesity. Evidence from randomized controlled trials and systematic reviews supports modest benefits on blood pressure, triglycerides, and LDL cholesterol, though results are inconsistent across studies. The active constituents are primarily anthocyanins and polyphenols in the calyces, which act via antioxidant, anti-inflammatory, and vasodilatory mechanisms. Overall evidence is promising but not yet conclusive, with researchers calling for larger, more rigorous trials.

7-HMR reduced multiple features of metabolic syndrome in HFD-fed mice including body weight gain, fat mass, liver steatosis, and serum lipids. Its metabolites modulate adipogenic and lipid-metabolism genes. Epidemiological data link dietary lignan intake with lower prevalence of metabolic and cardiovascular diseases.

In a high-fat diet mouse model specifically designed to induce metabolic syndrome, HMRlignan limited body weight gain (−11%), reduced fat mass (−11%), decreased liver steatosis (−62%), and improved sugar metabolism with a >70% decrease in insulin secretion and insulin resistance. These are preclinical findings with no human RCT confirmation.

Xanthohumol from hops significantly improved multiple metabolic syndrome markers—glucose, triglycerides, LDL cholesterol, insulin, and inflammatory cytokines—in animal studies. Mechanistically, XN inhibits SREBP activation and PCSK9, reducing de novo lipogenesis and LDL clearance impairment. Human data are emerging but remain limited.

HCA targets multiple components of metabolic syndrome simultaneously—reducing body weight, serum triglycerides, and cholesterol—through ATP-citrate lyase inhibition. Small RCTs in obese and NAFLD patients report improvements in several metabolic parameters, though effects are modest and inconsistent.

In HFD-induced metabolic syndrome in mice, HMR (3 mg/kg/day) limited body weight, fat mass, and implicitly improved the metabolic profile. A US patent claims 7-HMR for 'ameliorating metabolic syndrome conditions' including visceral obesity, dyslipidemia, high blood pressure, and high blood glucose. Evidence is currently animal and patent-level; human metabolic syndrome RCTs have not been published.

A randomised human study found H. italicum infusion more effective than H. arenarium at reducing body mass, fat mass, and inflammatory markers in patients with metabolic syndrome traits. Animal studies support anti-hyperglycaemic and insulin-sensitising effects of H. italicum extracts.

Inositol — primarily myo-inositol (MI) and D-chiro-inositol (DCI) — has been investigated in multiple randomized controlled trials and meta-analyses as an insulin-sensitizing supplement for metabolic syndrome. Clinical evidence shows significant improvements in HOMA-IR, fasting insulin, triglycerides, blood pressure, and total/LDL cholesterol in affected populations. Evidence quality is rated moderate-to-high for glycemic and lipid outcomes, though effect sizes are generally modest and some risk of bias exists across trials.

Inulin targets multiple components of metabolic syndrome simultaneously—glycemia, dyslipidemia, body weight, and inflammation—through prebiotic modulation of gut microbiota and SCFA production. An open-label pilot study in metabolic syndrome patients demonstrated gut microbiota restructuring with inulin supplementation. Evidence across individual components (blood sugar, triglycerides, weight) is stronger than for composite metabolic syndrome outcomes.

IMO addresses multiple components of metabolic syndrome—dyslipidemia, insulin resistance, obesity, and gut dysbiosis—in animal models. The 2024 PMC review identifies metabolic syndrome as a key potential application. Human clinical trial evidence is indirect, derived from individual MetS component outcomes.

A registered clinical trial (NCT05118698, First Affiliated Hospital Xi'an Jiaotong University) is investigating jiaogulan specifically in metabolic syndrome patients. Jiaogulan's effects on blood sugar, triglycerides, blood pressure, and abdominal obesity—the core components of metabolic syndrome—are individually supported by clinical evidence.

A prospective clinical study found that 8 weeks of daily kale powder consumption helped maintain optimal blood pressure, fasting blood sugar, and abdominal circumference in adults with potential metabolic syndrome. Kale's combination of fiber, antioxidants, and glucosinolates targets multiple metabolic syndrome risk factors simultaneously.

Kidney beans and their extract address multiple components of metabolic syndrome simultaneously: lowering fasting glucose, reducing LDL cholesterol, decreasing triglycerides, modestly lowering blood pressure, and supporting healthy weight. Clinical and preclinical evidence for WKBE specifically describes consistent reductions in metabolic risk markers.

Krill oil, rich in phospholipid-bound EPA and DHA plus the antioxidant astaxanthin, has been studied in clinical trials and meta-analyses for its effects on dyslipidemia—a core component of metabolic syndrome. A 2017 meta-analysis of 7 RCTs (662 participants) found significant reductions in LDL-C and triglycerides and a significant increase in HDL-C. However, a 2023 updated systematic review found no clinically meaningful effect of krill oil on blood pressure, fasting glucose, insulin resistance, BMI, or inflammatory markers, limiting its demonstrated benefit to the lipid profile component of metabolic syndrome rather than the syndrome as a whole.

Kudzu root and puerarin simultaneously target multiple components of metabolic syndrome—blood glucose, blood pressure, and lipids—as documented in both animal models and limited clinical studies. Puerarin improves insulin sensitivity, lowers blood pressure, and reduces cholesterol and triglycerides in metabolic disease models. The scientific literature from ScienceDirect specifically identifies metabolic syndrome as a key research focus for kudzu.

A landmark 18-month RCT by Monti et al. showed that L-arginine supplementation induced regression to normal glucose tolerance in patients with impaired glucose tolerance and metabolic syndrome. A 9-year extension follow-up found significantly decreased diabetes risk. L-arginine also addresses multiple metabolic syndrome components including insulin resistance, central adiposity, triglycerides, and blood pressure.

L-carnitine has been investigated in multiple randomized controlled trials and meta-analyses for its effects on the core biomarkers of metabolic syndrome (MetS). A 2020 systematic review and meta-analysis of RCTs found supplementation significantly reduced waist circumference and systolic blood pressure, with higher doses (>1 g/day) additionally improving fasting blood glucose, triglycerides, and HDL-cholesterol. Evidence is mixed, however: a 2022 double-blind RCT in MetS patients found no regression of carotid plaque and raised concerns about pro-atherogenic TMAO production as a counterbalancing risk.

L-Citrulline's precursor role in NO synthesis addresses multiple pillars of metabolic syndrome: endothelial dysfunction, hypertension, insulin resistance, and dyslipidemia. A comprehensive 2018 PMC review documented that watermelon-derived L-citrulline supplementation reduced blood pressure in human trials, with emerging evidence for lipid/lipoprotein benefits. Meta-analyses of RCTs confirm significant blood pressure reduction, and animal models show amelioration of the full metabolic syndrome phenotype.

Low glutathione levels are consistently observed in metabolic syndrome and the component conditions of insulin resistance, dyslipidemia, and hypertension. Preliminary human and animal trials with GSH augmentation in metabolic syndrome show improved outcomes. The GlyNAC clinical trial in older adults corrected multiple metabolic syndrome features including insulin resistance, inflammation, and endothelial dysfunction.

Plasma glycine is consistently lower in metabolic syndrome patients than in healthy controls. A published review of clinical and preclinical evidence concludes that glycine supplementation improves multiple components of metabolic syndrome including hyperglycemia, hypertension, hyperlipidemia, and obesity-related inflammation. RCTs document reductions in HbA1c, CRP, and blood pressure.

The evidence for L-histidine in metabolic syndrome is grounded in a dedicated RCT showing improvements across multiple MetS components: insulin resistance, inflammatory cytokines, oxidative stress, waist circumference, and fat mass. Mechanistically, histidine acts via anti-inflammatory, antioxidant, and hypothalamic histamine-mediated pathways.

L. casei Shirota has been studied in metabolic syndrome patients for intestinal permeability improvement, and L. casei LC2W was evaluated in a 2024 double-blind RCT in high-risk metabolic syndrome subjects for effects on glucose metabolism and gut microbiota. Evidence spans lipid profiles, glycemic control, and gut barrier function in this population, though individual trials are often small.

L. gasseri SBT2055 is specifically cited as having a protective effect against metabolic syndrome in rats and humans. It has been shown to reduce abdominal adiposity in RCTs, with associated improvements in metabolic parameters. Preclinical data demonstrate reductions in visceral fat, cholesterol, triglycerides, and inflammation relevant to metabolic syndrome components.

Multiple human clinical trials and systematic reviews support the use of Lactobacillus plantarum (now reclassified as Lactiplantibacillus plantarum) in addressing components of Metabolic Syndrome (MetS), including hyperglycemia, dyslipidemia, insulin resistance, and hypertension. Clinical evidence demonstrates improvements in fasting blood glucose, HbA1c, LDL-cholesterol, triglycerides, and blood pressure across several randomized controlled trials. The evidence is promising but remains strain-specific and heterogeneous across studies.

Lactobacillus rhamnosus, particularly the GG (LGG) and CGMCC1.3724 (LPR) strains, has been studied in human clinical trials and numerous preclinical models for its effects on key components of metabolic syndrome, including obesity, insulin resistance, dyslipidemia, and dysbiosis. A 2014 double-blind RCT found that L. rhamnosus LPR supplementation supported significant weight loss in obese women compared to placebo. A 2025 systematic review of 51 RCTs confirmed potential benefits of L. rhamnosus across metabolic and other conditions. Mechanistic evidence points to gut microbiota modulation, short-chain fatty acid production, improved GLP-1 secretion, and enhanced insulin sensitivity, though human evidence is still maturing and effects appear strain-dependent.

Studies on flax lignans combined with exercise training in individuals aged 50+ found reductions in diastolic blood pressure and triacylglycerols, as well as improvements across six metabolic syndrome risk factors including fasting glucose, HDL cholesterol, abdominal obesity, and inflammatory cytokines. Lignans have shown potential in mitigating conditions associated with metabolic syndrome.

Luteolin addresses multiple components of metabolic syndrome including dyslipidemia, hyperglycemia, hepatic steatosis, gut dysbiosis, and mitochondrial dysfunction in preclinical models. A human combination-product RCT in pre-obese subjects showed improvements in a broad cardiometabolic panel.

Lycopene has been investigated in the context of metabolic syndrome (MetS) components including low HDL, elevated triglycerides, hypertension, and abdominal obesity. A 2021 meta-analysis specifically found lycopene significantly improved HDL-c, a core MetS criterion. Mechanistic evidence supports lycopene's role in reducing oxidative stress and inflammation underlying MetS.

Tree nut meta-analyses including macadamia nuts show favorable effects on multiple components of metabolic syndrome—including fasting glucose, triglycerides, and cholesterol. Macadamia nuts' MUFA content and low glycemic profile address insulin resistance, dyslipidemia, and abdominal adiposity simultaneously. A meta-analysis of 47 RCTs found tree nuts significantly reduced triglycerides and fasting glucose in metabolic syndrome patients.

Substantial clinical and epidemiological evidence links magnesium status to metabolic syndrome (MetS). Low dietary magnesium intake and low serum magnesium are consistently associated with increased MetS risk across large meta-analyses. Supplementation has demonstrated reductions in CRP, fasting glucose, and blood pressure in RCTs, though effect sizes are modest and evidence on lipid profiles and overall MetS reversal remains mixed.

Maitake fractions address multiple components of metabolic syndrome—insulin resistance, hypertension, dyslipidemia, and inflammation—in animal models. Studies in aging rats show maitake fractions SX and D ameliorate progressive age-related hypertension, insulin insensitivity, and inflammatory markers. Traditional Asian use included metabolic syndrome-equivalent conditions.

Several human clinical studies have investigated mango's effects on metabolic syndrome components (blood glucose, blood pressure, lipids, inflammation, and body weight) with positive signals across multiple parameters. A systematic review (PMC 2024) covering 13 eligible human studies evaluated mango on cardiometabolic and metabolic syndrome endpoints.

In a rat model of diet-induced metabolic syndrome, maqui berry reduced all key MetS parameters: weight gain, fasting glucose, total cholesterol, triacylglycerides, insulin resistance, and blood pressure, while improving oxidative stress markers. In humans, the 3-month Delphinol trial addressed a prediabetic/MetS-risk population and showed favorable HbA1c, LDL, and HDL changes consistent with MetS risk reduction.

MCTs have been studied in the context of metabolic syndrome components—abdominal obesity, dyslipidemia, hypertension, and impaired fasting glucose—with some evidence of benefit versus LCT comparators. MCT supplementation has been reported to reduce metabolic syndrome features including abdominal obesity and inflammation. Effects depend heavily on the comparator fat and overall caloric context.

Milk thistle (Silybum marianum) and its primary extract silymarin have been studied in multiple human randomized controlled trials and meta-analyses for core components of metabolic syndrome, including insulin resistance, dyslipidemia, hyperglycemia, and non-alcoholic fatty liver disease (NAFLD). A 2020 meta-analysis of 16 RCTs (1,358 patients) found silymarin supplementation significantly reduced fasting blood glucose, HOMA-IR, and triglycerides while improving HDL-C. A separate meta-analysis in type 2 diabetes (5 RCTs, 270 patients) found significant reductions in fasting glucose (−26.86 mg/dL) and HbA1c (−1.07%), though evidence quality is rated as low-to-moderate due to heterogeneity across trials. Clinical evidence supports biological plausibility, but large, well-designed trials focused specifically on metabolic syndrome as a composite endpoint remain limited.

Millets collectively address multiple components of metabolic syndrome, including elevated blood glucose, dyslipidemia, hypertension, and excess body weight. Systematic review data confirm simultaneous improvements in all four modifiable metabolic syndrome risk factors with regular millet consumption. Millet is specifically proposed as a low-GI food for metabolic syndrome management.

Momordica charantia has been specifically evaluated for metabolic syndrome (MetS) parameters including glycaemia, lipids, blood pressure, and body weight in multiple human RCTs. A 2024 meta-analysis of nine RCTs found that M. charantia mono preparations did not significantly improve any individual MetS parameter versus placebo, but studies were short and underpowered.

Monk fruit extract addresses several components of metabolic syndrome including hyperglycemia, dyslipidemia, and excess adiposity through its zero-calorie sweetening, mogroside-mediated glycemic modulation, and preclinical lipid-lowering effects. The 2025 PRISMA systematic review of human RCTs specifically assessed MFE's impact on metabolic health and lipid profiles. Animal studies demonstrate improvements in multiple metabolic syndrome markers simultaneously.

M. citrifolia demonstrates activity across multiple components of metabolic syndrome: reduced cholesterol, LDL, and triglycerides; improved blood glucose; lower blood pressure; and reduced systemic inflammation (hs-CRP). A dedicated PMC review (2017) examined its potential in obesity-related metabolic dysfunction.

Morus alba extract addresses multiple components of metabolic syndrome simultaneously, including elevated glucose, triglycerides, blood pressure, and inflammation. A 2025 meta-analysis of 15 RCTs specifically assessed mulberry extract for metabolic risk factors and confirmed significant pooled improvements across all major metabolic syndrome parameters.

Mulberry leaf extract addresses all core components of metabolic syndrome—visceral obesity, insulin resistance, dyslipidaemia, hypertension, and inflammation—across multiple in vivo and clinical studies. A systematic review of 15 studies confirmed favourable effects on metabolic syndrome-related factors.

TC addresses multiple components of metabolic syndrome simultaneously: blood glucose, cholesterol, triglycerides, and endothelial dysfunction. RCT data in type 2 diabetic patients with dyslipidemia confirm multi-parameter improvements, while the joint comfort trial enrolled overweight subjects — a core metabolic syndrome population.

N-Acetyl Cysteine (NAC) has direct human clinical evidence supporting its use in metabolic syndrome. As a glutathione precursor with antioxidant and anti-inflammatory properties, NAC targets the oxidative stress and chronic inflammation that underpin metabolic syndrome. A randomized, double-blind, placebo-controlled trial in MetS patients found that 1800 mg/day of NAC for 12 weeks significantly improved fasting glucose, insulin resistance, HDL-cholesterol, and CRP. Evidence base is promising but still limited in scale, and larger trials are needed.

A 2019 systematic review of 19 studies concluded naringin alleviates metabolic syndrome components—visceral obesity, hyperglycemia, hypertension, and dyslipidemia—by preventing oxidative damage and suppressing pro-inflammatory cytokines. Human clinical data show naringin reduces BMI, total cholesterol, LDL, and raises adiponectin in dyslipidemic patients. Adequate human RCTs for the full MetS cluster are still lacking.

Clinical trials examining NMN's cardiometabolic effects have shown variable results, with some studies in metabolically compromised individuals (elevated BMI, hypertension, prediabetes) showing improvements in blood pressure, body weight, and insulin sensitivity. A 2024 review found NMN's effects on metabolic parameters are context-dependent and more pronounced in individuals with metabolic dysregulation.

Several human RCTs have specifically studied nopal in subjects with metabolic syndrome, showing improvements in glucose, triglycerides, C-reactive protein, body weight, BMI, and waist circumference. A 6-week RCT improved HDL and LDL in women with metabolic syndrome. A 2-month RCT with a nopal-containing formula reduced multiple cardiometabolic risk factors. Evidence quality is moderate, primarily from small to medium trials.

C. rotundus addresses multiple components of metabolic syndrome: anti-hyperglycemic, hypolipidemic, antihypertensive, and anti-obesity effects are all documented pharmacologically. Human RCTs confirm weight and lipid parameter improvements. The 2024 PMC study demonstrated multi-mechanism protection against obesity and diabetes simultaneously in animal models.

Oat β-glucan addresses multiple components of metabolic syndrome simultaneously—LDL cholesterol, blood glucose, blood pressure, and weight—with documented clinical evidence for each. A 2012 review concluded β-glucan has beneficial roles in insulin resistance, dyslipidemia, hypertension, and obesity characteristic of metabolic syndrome.

Okra addresses multiple components of metabolic syndrome including dysglycemia, dyslipidemia, and elevated inflammatory markers. A PubMed-indexed review specifically evaluates okra's effect on metabolic syndrome. Clinical trial evidence shows significant reductions in TC, LDL, FBG, and HbA1c—core metabolic syndrome parameters—in diabetic and prediabetic populations.

OA addresses multiple components of metabolic syndrome simultaneously—hyperglycemia, dyslipidemia, hypertension, and obesity—making it a candidate treatment agent according to a 2019 systematic review. A human crossover study with olive oil triterpenoids (including OA) reported reductions in DNA oxidation and plasma inflammatory biomarkers.

A 2021 systematic review and meta-analysis of human trials found that olive oil and oleic acid intake have beneficial effects on the key components of metabolic syndrome, including dyslipidaemia, insulin resistance, hypertension, and obesity. OEA, the primary bioactive metabolite of oleic acid, addresses inflammation, triglyceride dysregulation, glycaemic control, and insulin resistance—all core MetS features.

OLE and combined olive leaf/fruit extract preparations have been assessed in clinical trials for metabolic syndrome components including blood pressure, triglycerides, fasting glucose, HDL-C, and waist circumference. A large pilot study in 663 (pre-)hypertensive patients showed significant improvements in MetS markers over 2 months. OLE addresses multiple MetS components simultaneously.

Multiple RCTs and meta-analyses demonstrate that EVOO, as part of a Mediterranean diet, improves the key components of metabolic syndrome: blood pressure, fasting glucose, insulin resistance, lipid profile, and waist circumference. Olive polyphenols independently (beyond lipid content) reduce metabolic syndrome risk factors.

Omega-3 fatty acids (primarily EPA and DHA) have robust clinical evidence supporting their role in addressing multiple components of Metabolic Syndrome (MetS), including hypertriglyceridemia, insulin resistance, hypertension, and systemic inflammation. A 2019 systematic review and meta-analysis of 13 studies (n=36,542) found higher omega-3 PUFA intake or blood levels associated with a 26% reduction in MetS risk. The strongest and most consistent effect is triglyceride lowering; effects on HDL, blood pressure, and glycemia are documented but more variable across trials.

Omega-6 PUFAs, particularly linoleic acid, are associated with improved blood lipoprotein profiles and delayed development of type 2 diabetes—key components of metabolic syndrome. A systematic review of clinical trials found that omega-6 fatty acids improved blood lipids and delayed diabetes mellitus, with positive effects on insulin resistance through PUFA replacement of saturated fats. Evidence is observational and mechanistic; dedicated metabolic syndrome RCTs are sparse.

Palmitoleic acid has been studied in the context of metabolic syndrome due to its effects on multiple components: inflammation (hs-CRP reduction), dyslipidemia, and insulin sensitivity. Human RCT data show simultaneous improvements in CRP, triglycerides, LDL, and HDL—key metabolic syndrome markers—with purified omega-7 supplementation. Epidemiological evidence from the Cardiovascular Health Study links higher plasma palmitoleate to lower metabolic syndrome risk.

Oleic acid (omega-9) addresses multiple components of metabolic syndrome—including dyslipidemia, insulin resistance, blood pressure, and inflammation—through PPAR activation, AMPK signaling, and NF-κB suppression. Mediterranean dietary patterns rich in OA are associated with reduced metabolic syndrome prevalence and severity.

Onion addresses multiple components of metabolic syndrome simultaneously: reducing blood pressure, improving lipid profiles, lowering fasting glucose, and improving body fat percentage. A dedicated PMC review examined A. cepa specifically as a cardiovascular protectant in metabolic syndrome risk factors. Multiple RCTs and meta-analyses confirm benefits across individual components.

Orange flavonoids, particularly hesperidin and anthocyanins in blood orange, have been studied for multiple components of metabolic syndrome, including dyslipidaemia, insulin resistance, elevated blood pressure, and inflammation. Clinical and pre-clinical evidence supports benefits on several MetS components simultaneously, especially in overweight individuals.

Oyster mushrooms have been studied for effects on several components of metabolic syndrome—elevated blood glucose, dyslipidemia, hypertension, and excess adiposity. A dedicated review (ScienceDirect, 2024) examined P. ostreatus/eryngii mechanisms across MetS parameters. Clinical data from multiple trials cover individual MetS components, though no single trial has used MetS resolution as a primary composite endpoint.

Palm tocotrienol-rich fraction (TRF) has been shown in animal models to reverse multiple hallmarks of metabolic syndrome including hypertension, dyslipidemia, hyperglycemia, and hepatic steatosis. Human clinical data include a crossover RCT showing 400 mg/day TRF is well-tolerated in metabolic syndrome subjects, and evidence that tocotrienol supplementation improves cardiometabolic biomarkers.

Chronic elevation of palmitic acid—from dietary sources or de novo lipogenesis—is mechanistically linked to the core features of metabolic syndrome: insulin resistance, dyslipidemia, inflammation, and hepatic steatosis. Clinical and epidemiological data associate high palmitic acid exposure with each individual component of the syndrome.

POA is a lipokine implicated in key components of metabolic syndrome including dyslipidemia, hyperglycemia, and abdominal obesity. Prospective cohort evidence is complex: exogenous/dietary POA is associated with improved metabolic parameters, but endogenous esterified POA as a de novo lipogenesis marker can associate with elevated MetS risk.

Pantethine, a derivative of vitamin B5 and precursor to Coenzyme A, has clinical evidence supporting its use in addressing the dyslipidemia central to metabolic syndrome—specifically reducing triglycerides, LDL, and total cholesterol while raising HDL. More than 28 clinical trials have documented these effects, with typical reductions of 15–20% in LDL, up to 36% in triglycerides, and an ~8% rise in HDL over 4–9 months. Its lipid profile closely matches the high-TG/low-HDL pattern characteristic of metabolic syndrome, and it has additionally been studied in diabetic dyslipidemia and hepatic steatosis, which frequently co-occur with the syndrome.

Pea's multi-component profile—protein, fiber, and bioactive peptides—addresses multiple features of metabolic syndrome including blood glucose, blood pressure, lipids, and adiposity. DPP-IV and ACE inhibitory peptides in pea hydrolysates may have combined anti-diabetic and antihypertensive effects.

Peach leaf extract significantly mitigated multiple features of metabolic syndrome in a high-fructose rat model, reducing body weight gain, insulin resistance, glycemia, total cholesterol, and triglycerides. Polyphenol-rich peach by-products showed similar effects in obese rats. Evidence is animal-only.

Regular nut consumption, including peanuts, is associated with favourable effects on multiple components of metabolic syndrome including blood pressure, visceral adiposity, lipids, and insulin resistance. Peanut-derived resveratrol has been studied in metabolic syndrome contexts. Clinical and epidemiological data support peanuts as part of dietary management of MetS.

Pectin-enriched formulations have demonstrated significant improvements across multiple components of metabolic syndrome — including fasting glucose, triglycerides, cholesterol, HOMA-IR, and body weight — in a double-blind human RCT. Pectin's prebiotic and lipid-modulating properties address the core pathophysiology of the condition.

Berberine, the key alkaloid in P. amurense, has been evaluated specifically in metabolic syndrome patients in clinical trials, showing improvements in blood glucose, lipids, and inflammatory markers. A 2025 systematic review and meta-analysis of RCTs confirmed berberine significantly reduces triglycerides, fasting plasma glucose, LDL-C, total cholesterol, BMI, and waist circumference in metabolic syndrome. A 2018 RCT in 80 metabolic syndrome patients reported significant improvements with berberine treatment.

Metabolic syndrome is associated with impaired phospholipid metabolism, including altered phosphatidylcholine/lysophosphatidylcholine ratios linked to reduced LCAT activity and HDL dysfunction. PC is integral to VLDL assembly and hepatic lipid export, processes disrupted in metabolic syndrome. EPL/PC treatment improves liver enzyme profiles in NAFLD patients with metabolic comorbidities.

Multiple RCTs and a 2025 systematic review of 14 RCTs demonstrate that phytosterol supplementation modestly improves several metabolic syndrome components including LDL-cholesterol, triglycerides, systolic blood pressure, and fasting glucose. Effects on waist circumference and HDL are minimal. Evidence supports phytosterols as adjuncts in metabolic syndrome management.

Systematic reviews confirm Pycnogenol improves multiple components of metabolic syndrome including blood glucose, blood pressure, waist circumference, and lipid profile. A Wiley review and meta-analysis support improvements in endothelial and renal function in metabolic syndrome patients. It is considered appropriate for targeting the multifaceted pathophysiology of this condition.

Plant sterols address several components of metabolic syndrome, particularly elevated LDL-C and triglycerides. Clinical studies in individuals with metabolic syndrome show significant reductions in LDL-C and triglycerides, and one RCT also found blood pressure benefits when combined with a healthy dietary pattern. Effects appear more pronounced in metabolic syndrome patients than in normolipidemic subjects.

Policosanol, a mixture of very long-chain aliphatic alcohols derived primarily from sugarcane wax, has been studied in human clinical trials for its effects on the core components of metabolic syndrome—dyslipidemia, hypertension, and oxidative stress. A 2020 randomized, double-blind, placebo-controlled trial in 100 metabolic syndrome patients found significant improvements in LDL-C, HDL-C, total cholesterol, apolipoprotein B, and oxidative stress markers over 6 months at 10 mg/day. However, evidence on some components (especially triglycerides and blood glucose) is weaker, and several non-Cuban independent studies have failed to replicate the lipid-lowering findings, leaving the overall evidence body mixed but clinically grounded.

A systematic review of clinical studies (PMC9032502) confirmed pomegranate beneficially affects all five core components of metabolic syndrome: blood pressure, glycemia, triglycerides, total cholesterol, and body weight, while also improving HDL and insulin resistance. Early research also shows improved blood vessel function in adolescents with metabolic syndrome after pomegranate juice.

Pomelo's dominant flavonoids naringin and naringenin address multiple components of metabolic syndrome including hyperlipidemia, hyperglycemia, hypertension, and visceral obesity. A systematic review concluded naringin prevents metabolic syndrome through inhibition of oxidative stress and proinflammatory cytokines. Pomelo peel extracts activating PPARα and GLUT4 pathways prevent high-fat diet-induced metabolic disorders in mice.

Opuntia fiber and cladode preparations have demonstrated clinical reductions in multiple metabolic syndrome components including total cholesterol, LDL, triglycerides, blood glucose, and body fat percentage. One proprietary RCT showed significant reductions in body weight and BMI in overweight adults.

A peer-reviewed ScienceDirect review (2020) is specifically focused on the health benefits of Prunus species in metabolic syndrome risk factors, which include hypertension, hyperglycemia, dyslipidemia, and abdominal obesity. Multiple Prunus species components (polyphenols, phytosterols, fiber) address each component of the metabolic syndrome cluster via distinct but complementary mechanisms, with supporting human trial data.

Psyllium husk has robust human clinical evidence supporting its use across multiple components of metabolic syndrome (MetS). Randomized controlled trials and meta-analyses demonstrate significant reductions in LDL cholesterol, fasting blood glucose, and systolic blood pressure in MetS patients. Its gel-forming, viscous soluble fiber works via bile acid sequestration and slowed nutrient absorption, directly addressing the dyslipidemia, hyperglycemia, and hypertension that define MetS.

P. marsupium addresses multiple components of metabolic syndrome including hyperglycemia, dyslipidemia, obesity, and insulin resistance in preclinical models. The sum of published evidence justifies a scientific classification for the metabolic syndrome cluster.

Pumpkin seed protein has demonstrated comprehensive amelioration of fructose-induced metabolic syndrome features in rats, including normalisation of blood glucose, insulin, blood pressure, triglycerides, cholesterol, and liver oxidative stress. Its phytosterols and unsaturated fatty acids address multiple metabolic syndrome components simultaneously.

Preclinical evidence supports B. diffusa activity across multiple metabolic syndrome components simultaneously: antihyperglycemic, antihyperlipidemic (cholesterol, triglycerides), anti-obesity (cannabinoid receptor blocking in high-fat-diet rats), and antihypertensive effects have all been documented in animal models. No integrated human metabolic syndrome trial has been conducted.

A dedicated review (PMC, 2022) examined purslane's role across all components of metabolic syndrome—obesity, hypertension, dyslipidemia, and hyperglycemia—and found evidence from in vitro, animal, and human studies supporting improvements across multiple MetS parameters. RCT evidence confirms effects on blood glucose, lipids, blood pressure, and body weight, though no single large RCT has addressed all MetS criteria simultaneously.

Multiple randomized controlled trials and meta-analyses have examined quercetin's effects on the core components of metabolic syndrome (MetS) — elevated blood glucose, dyslipidemia, hypertension, and systemic inflammation. A 2024 dose-response meta-analysis of 20 RCTs found significant reductions in fasting blood glucose and systolic blood pressure. A separate meta-analysis of 16 RCTs showed significant decreases in total cholesterol, LDL-cholesterol, and CRP. Clinical evidence is real but still limited in scale and effect size, and some MetS components such as triglycerides, HDL, and waist circumference showed no significant change.

A dose-response RCT in 50 overweight/obese adults found that 50 g/day of quinoa for 12 weeks reduced serum triglycerides and lowered metabolic syndrome prevalence by 70%. The 25 g/day group saw a 40% MetS prevalence reduction. Quinoa addresses multiple MetS criteria simultaneously—TG, glucose, blood pressure, and waist circumference—through its fiber, polyphenols, and unsaturated fatty acid content.

Red Yeast Rice (RYR) has direct clinical evidence supporting its use across multiple components of Metabolic Syndrome (MetS). Its active constituent, monacolin K — chemically identical to the statin lovastatin — inhibits HMG-CoA reductase, lowering LDL cholesterol, triglycerides, and total cholesterol. A 2022 systematic review and meta-analysis of 30 RCTs (n=5,440) published in Frontiers in Pharmacology found RYR preparations significantly reduced mortality, major cardiovascular events, fasting glucose, HbA1c, insulin resistance, and blood pressure in MetS patients. Evidence is strongest for dyslipidemia management; effects on abdominal obesity remain less studied.

Reishi has demonstrated effects on multiple components of metabolic syndrome in preclinical models: reducing blood glucose, insulin resistance, triglycerides, visceral adiposity, and gut dysbiosis in obese/high-fat-diet animal models. Human clinical evidence addresses individual components (blood sugar, lipids) rather than metabolic syndrome as a composite diagnosis. TCM used reishi for related conditions of excess and depletion.

Resveratrol has been extensively studied in human clinical trials for its effects on metabolic syndrome (MetS) components including blood pressure, glucose, lipids, and body composition. Preclinical evidence is robust, but human trial results are mixed and often inconclusive. A 2024 meta-analysis found significant reductions in systolic and diastolic blood pressure, while effects on waist circumference, HDL, and triglycerides were inconsistent or unfavorable. One well-powered RCT found no benefit—and some adverse lipid changes—at high doses in men with MetS.

A systematic review and meta-analysis of RCTs directly examined caffeinated and decaffeinated Coffea robusta (among other coffee species) on metabolic syndrome parameters and found modulation of multiple components including glycaemic, lipid, and inflammatory markers. A rat model of metabolic syndrome found that robusta coffee leaves increased total antioxidant status, a key protective factor against metabolic syndrome progression.

Rosmarinic acid targets multiple components of metabolic syndrome simultaneously in preclinical models: reducing blood pressure (via ACE inhibition), lowering blood glucose and improving insulin sensitivity, reducing plasma triglycerides and cholesterol, and decreasing systemic inflammatory tone. This multi-target activity makes RA a candidate for metabolic syndrome management.

RJ addresses multiple components of metabolic syndrome across RCTs: it reduces fasting blood glucose and HbA1c in diabetic patients, lowers total cholesterol and LDL, reduces CRP, and increases adiponectin. No single RCT has targeted metabolic syndrome as a composite endpoint.

Rutin simultaneously targets multiple components of metabolic syndrome including elevated blood glucose, dyslipidemia, hypertension, and systemic inflammation. Clinical data show improvements in cardiometabolic biomarkers in diabetic patients, and one study in metabolic syndrome subjects reported significant reductions in CRP and oxidative stress after 90 days.

Whole-grain rye has been directly tested in metabolic syndrome populations in RCTs, demonstrating favorable effects on blood lipids (LDL reduction), lipid biomarker profiles, and triglyceride associations. The SYSDIET study and the 2020 crossover RCT both enrolled metabolic syndrome subjects and found rye-specific cardiometabolic improvements. Rye's multi-component dietary fiber matrix addresses several metabolic syndrome criteria simultaneously.

A 2021 randomized, double-blind, placebo-controlled trial in 67 metabolic syndrome patients found 8 g/day safflower oil for 12 weeks significantly reduced waist circumference, systolic blood pressure, and insulin resistance. Safflower has been used across Persian, Chinese, Korean, and Japanese traditional medicine for metabolic disorders. Evidence spans clinical trial, animal model, and in vitro mechanistic data.

Multiple RCTs and systematic reviews document saffron's beneficial effects on the cluster of metabolic syndrome components: hyperglycemia, dyslipidemia, hypertension, and abdominal obesity. A 2020 systematic review of 14 RCTs in patients with diabetes mellitus and metabolic syndrome confirmed improvements in blood glucose, lipid profile, and blood pressure markers.

A preclinical study on Smilax aristolochiifolia demonstrated significant reductions in weight gain, hypertriglyceridemia, insulin resistance, and hypertension in obese mice. Drugs.com acknowledges effects on cardiovascular risk factors and metabolic syndrome in animal/in vitro research. No human clinical trials for metabolic syndrome have been conducted.

The British Journal of Nutrition concluded that SDG metabolites protect against the metabolic syndrome by reducing lipid and glucose concentrations, lowering blood pressure, and decreasing oxidative stress and inflammation. SDG targets multiple metabolic syndrome components simultaneously: dyslipidemia, hyperglycemia, central obesity, and hypertension. A human RCT in type 2 diabetics confirmed FLC/SDG reduced waist circumference gain and improved glucose markers.

Sesame supplementation targets multiple components of metabolic syndrome simultaneously: blood pressure, fasting glucose, HbA1c, LDL cholesterol, and triglycerides are all reduced in clinical trials. A 2025 GRADE-assessed meta-analysis (13 RCTs, 521 participants) and a 2024 meta-analysis in T2DM (13 RCTs, 731 participants) both confirm multi-domain cardiometabolic benefits consistent with metabolic syndrome management.

Shiitake addresses multiple components of metabolic syndrome simultaneously: it lowers LDL cholesterol, reduces triglycerides, attenuates weight gain on a high-fat diet, and improves insulin sensitivity markers. A human RCT showed improved HOMA-IR in prediabetic subjects. The gut microbiome modulation by shiitake polysaccharides may further mediate metabolic effects.

Silymarin addresses multiple components of metabolic syndrome (hyperglycemia, dyslipidemia, hypertension, insulin resistance) in human and experimental studies. A 2018 PubMed review of human and experimental data concluded silymarin has promising effects on insulin resistance, blood pressure, and lipid profile. The 2024 dose-response meta-analysis (33 trials) confirmed significant reductions in FBG, TG, TC, LDL, diastolic BP, and fasting insulin.

Clinical trials specifically in metabolic syndrome subjects show that plant stanol esters lower both LDL cholesterol and serum triglycerides, with larger TG reductions than in normolipidaemic populations. Studies document significant decreases in large and medium VLDL particles in these subjects. A phytosterol RCT in 202 metabolic syndrome subjects found a 15.65% greater reduction in the proportion with high triglycerides versus placebo.

Multiple RCTs and meta-analyses show soy protein and isoflavone supplementation favorably affect several metabolic syndrome components, including fasting glucose, insulin resistance (HOMA-IR), LDL cholesterol, total cholesterol, diastolic blood pressure, and CRP. Effects are most robust for lipid and glycemic markers.

Multiple RCTs in patients with metabolic syndrome show that soy isoflavone supplementation reduces triglycerides, LDL cholesterol, total cholesterol, and waist circumference. A dedicated RCT in older women with metabolic syndrome supports these findings.

Several randomized clinical trials have assessed soy's effects on multiple components of metabolic syndrome, finding improvements in lipid profiles, insulin levels, waist circumference, and blood pressure. A PMC review (2021) specifically examined soy isoflavones for metabolic syndrome prevention, finding evidence for lipid profile improvement and oxidative stress reduction. Effects are most consistent for lipid parameters, with glucose effects being less reliable.

The Meratrim blend (S. indicus + G. mangostana) addresses multiple components of metabolic syndrome simultaneously: body weight, BMI, waist circumference, blood glucose, triglycerides, and blood pressure. A meta-analysis of 3 RCTs confirms clinically significant improvements across these cardiometabolic parameters in obese subjects.

Spinach thylakoids and nitrate address multiple components of metabolic syndrome: thylakoids reduce weight, appetite, and postprandial insulin; nitrate lowers blood pressure and improves vascular function. A recent RCT in obese men evaluated combined thylakoid supplementation and exercise on adipo-myokine profiles relevant to metabolic dysregulation.

A systematic review of 13 human clinical studies confirmed spirulina supplementation has a positive effect on metabolic syndrome, improving blood pressure, blood sugar, lipid profiles, and body weight simultaneously. An RCT in 40 metabolic syndrome subjects found a spirulina liquid extract decreased urinary isoprostanes and plasma triglycerides while increasing HDL-cholesterol. The active bioactives phycocyanin, Ile-Gln-Pro, gamma-linolenic acid, and glycolipid H-b2 are identified as mechanistic drivers.

Obese patients with metabolic syndrome show blunted SPM production capacity despite omega-3 supplementation, documented in a human RCT. SPMs reduce adipose tissue inflammation, improve insulin sensitivity, and attenuate the chronic low-grade inflammation characteristic of metabolic syndrome. Inadequate SPM levels are confirmed in human metabolic disease tissue.

Stevia's combined effects on blood glucose, blood pressure, and lipid profile address multiple components of metabolic syndrome. Animal and some human evidence support stevia's relevance to metabolic syndrome management. A 2020 review identified stevia as a potentially safer non-nutritive sweetener for metabolic syndrome given its glycemic and antihypertensive effects, without raising blood glucose.

Steviol glycosides address several components of metabolic syndrome simultaneously in human RCTs: fasting blood glucose reduction, significant systolic BP reduction, and non-significant favorable trends in BMI, cholesterol, and HDL. No dedicated RCT has used metabolic syndrome as a primary composite endpoint, but multiple individual biomarkers have been tested.

Several RCTs specifically conducted in adults with metabolic syndrome show strawberry supplementation reduces atherosclerotic and inflammatory biomarkers, improves lipid peroxidation, and reduces CRP and small-dense LDL particles. Freeze-dried strawberry powder at 25–50 g/day improved lipid profiles and lipid peroxidation in women with metabolic syndrome. Strawberry intake also attenuated meal-induced inflammatory and thrombotic responses in overweight individuals.

Succinic acid–based supplements improved body weight, waist circumference, and apolipoprotein levels in menopausal RCTs, and animal studies show favorable effects on central adiposity, lipid profiles, and adipose tissue metabolism. The SUCNR1 signaling pathway links succinate to adipose inflammation and glucose intolerance relevant to metabolic syndrome.

Sulforaphane simultaneously addresses multiple components of metabolic syndrome—insulin resistance, dyslipidemia, oxidative stress, and low-grade inflammation—via concurrent Nrf2, NF-κB, and PPARγ modulation. Human RCTs in T2DM show improvements in several metabolic syndrome biomarkers.

Taurine has meaningful clinical evidence supporting its role in addressing multiple components of metabolic syndrome (MetS). A 2024 systematic review and meta-analysis of 25 RCTs (1,024 participants) published in Nutrition & Diabetes found statistically significant reductions in systolic and diastolic blood pressure, fasting blood glucose, and triglycerides with taurine supplementation. Proposed mechanisms include improved insulin sensitivity, enhanced bile acid synthesis reducing cholesterol, anti-inflammatory effects, and modulation of the renin-angiotensin system. Evidence is promising but limited by small trial sizes, dosage variability, and short follow-up periods.

A 2021 systematic review specifically examined iso-α-acids including THIAA against metabolic syndrome and its related disorders (diabetes, dyslipidemia, inflammation) using PubMed/Scopus. THIAA reduced body weight gain, fat mass, glucose intolerance, and metabolic endotoxemia in HFD mice. Iso-alpha acid class compounds have been studied in human interventional trials for metabolic syndrome components.

T. cordifolia addresses multiple components of metabolic syndrome—hyperglycemia, hypertriglyceridemia, low HDL, and dyslipidemia—in both human and animal studies. A human pilot trial showed significant reductions in triglycerides and VLDL with increased HDL. Its anti-inflammatory and insulin-sensitizing actions are mechanistically relevant.

TMG addresses several components of metabolic syndrome simultaneously: it lowers homocysteine, may improve insulin sensitivity, reduces hepatic lipid accumulation and inflammation, and supports methylation pathways that are commonly disrupted in metabolically unhealthy individuals. Betaine supplementation is documented to inhibit inflammation and improve insulin resistance in liver disease reviews. Evidence in specifically diagnosed metabolic syndrome patients is limited.

Clinical trials show tocotrienols improve multiple metabolic syndrome components simultaneously, including fasting glucose, blood pressure, HDL-cholesterol, and triglycerides. A 12-week RCT with tocotrienol-enriched oats in metabolic syndrome patients showed remission rates approximately double those of control.

A randomized controlled dietary intervention (8 weeks, postmenopausal women) found a tomato-rich diet significantly reduced body fat, waist circumference, total cholesterol, triglycerides, systolic blood pressure, and blood sugar, while raising HDL—collectively improving all major metabolic syndrome criteria. Serum lycopene levels are also inversely associated with metabolic syndrome risk in epidemiological studies.

Pterostilbene has been studied as a PPAR-α agonist with effects on blood pressure, lipids, blood glucose, and body weight—the core components of metabolic syndrome. The primary human RCT directly enrolled hypercholesterolemic adults and measured metabolic parameters including lipids, blood pressure, and weight.

Triphala addresses multiple components of metabolic syndrome simultaneously—elevated blood glucose, dyslipidemia, and excess body weight—as documented in a 2021 systematic review of 12 RCTs (749 patients). It also shows preclinical effects on adiponectin, SOD, and hepatic fat accumulation relevant to metabolic syndrome.

Curcumin, the principal bioactive of turmeric (Curcuma longa), has been evaluated in multiple randomized controlled trials (RCTs) and meta-analyses specifically in patients with metabolic syndrome (MetS). Pooled evidence shows significant improvements in fasting blood glucose, triglycerides, HDL-cholesterol, diastolic blood pressure, and waist circumference. Mechanistically, curcumin exerts anti-inflammatory and antioxidant effects and modulates insulin sensitivity, lipid metabolism, and nitric oxide pathways. Overall evidence quality is moderate; larger, methodologically rigorous trials are still needed.

Multiple RCTs and a meta-analysis in metabolic syndrome patients show CoQ10 supplementation improves adipokine levels, reduces lipid peroxidation, lowers blood pressure, and modulates insulin sensitivity—addressing multiple components of metabolic syndrome simultaneously. CoQ10 levels are altered in metabolic syndrome, with ubiquinol/ubiquinone ratios serving as a marker of oxidative stress in this population.

Vanadyl sulfate has been investigated in animal models of metabolic syndrome (fructose-induced obesity), normalizing blood glucose, triglycerides, and insulin levels. Human clinical trial data show improvements in multiple metabolic syndrome components—HbA1c, LDL-C, triglycerides, and BMI—in T2DM patients, which overlap substantially with metabolic syndrome criteria.

Vanadyl sulfate addresses multiple components of metabolic syndrome—insulin resistance, hyperglycemia, dyslipidemia, and hyperinsulinemia—in both human and animal models. Evidence in humans is primarily from diabetic populations; animal models using fructose-induced obesity directly model the metabolic syndrome cluster.

Thiamine deficiency is linked to the progressive atherosclerosis commonly observed in metabolic syndrome, and clinical trials show thiamine supplementation improves endothelial function and blood pressure in hyperglycemic patients. Thiamine's role in glucose metabolism and oxidative stress reduction is mechanistically central to metabolic syndrome pathophysiology.

Niacin (vitamin B3) directly targets the atherogenic dyslipidemia that defines metabolic syndrome—elevated triglycerides, low HDL-cholesterol, and small dense LDL particles—through several established lipid-modulating mechanisms. Multiple randomized controlled trials in metabolic syndrome populations document significant improvements in HDL-C, triglycerides, and lipoprotein subfractions. A key limitation is that niacin can worsen insulin resistance, a core feature of metabolic syndrome, and large cardiovascular outcome trials (AIM-HIGH, HPS2-THRIVE) failed to demonstrate reduced cardiovascular events when niacin was added to statin therapy.

Substantial clinical and observational evidence links low vitamin D status with metabolic syndrome (MetS) and its individual components — insulin resistance, dyslipidemia, hypertension, and abdominal obesity. Multiple RCTs and meta-analyses confirm that vitamin D supplementation can modestly improve select MetS parameters, particularly glycemic indices and blood pressure in deficient individuals, though effects on lipids and body composition are inconsistent. Overall evidence quality ranges from low to moderate, and causality has not been firmly established.

Substantial clinical and epidemiological evidence links vitamin D3 deficiency to metabolic syndrome (MetS), with observational meta-analyses consistently showing an inverse association between serum 25(OH)D and MetS risk. Randomized controlled trials (RCTs) and their meta-analyses suggest vitamin D3 supplementation may modestly reduce fasting glucose, triglycerides, and insulin resistance, particularly in deficient individuals. However, causality remains contested: some meta-analyses find no significant improvement in metabolic parameters, leaving the observed association partly attributable to confounding. The evidence base is scientific but the therapeutic benefit is not firmly established.

Vitamin E, particularly tocotrienol forms, has been studied in multiple human trials for components of metabolic syndrome including dyslipidemia, hyperglycemia, and hypertension. A Frontiers in Pharmacology review of human studies found benefits across most metabolic syndrome parameters in vitamin E-supplemented diabetic and hyperlipidemic patients, though evidence is heterogeneous.

In a rat model of diet-induced metabolic syndrome, wasabi supplementation reduced body weight, blood pressure, plasma cholesterol, triglycerides, and cardiac inflammation simultaneously. 6-MSITC's pleiotropic effects on PPAR, AMPK, NF-κB, and Nrf2 pathways address multiple components of metabolic syndrome. It is listed as a candidate treatment for metabolic syndrome in a 2024 PMC systematic review, though human evidence is absent.

Whole-grain wheat consumption is associated with improved metabolic syndrome criteria, including reduced visceral fat, improved blood pressure, and modest improvements in blood glucose and lipid markers. RCTs in adults with elevated waist circumference show whole-grain wheat diets improve adiposity and blood pressure components of MetS. Arabinoxylan from wheat targets multiple MetS components via microbiota modulation and SCFA production.

A 2020 systematic review and meta-analysis specifically examined wheat germ's effect on metabolic syndrome markers (cholesterol, triglycerides, glucose, oxidative stress) across 10 RCTs. Aggregate effects were statistically non-significant. However, one RCT in T2DM patients (20 g/day) showed total cholesterol reduction, and animal data support wheat germ in ameliorating insulin resistance and cardiac mitochondrial dysfunction.

A meta-analysis of 22 RCTs in patients with metabolic syndrome and related conditions found whey protein significantly reduced HbA1c, fasting insulin, HOMA-IR, triglycerides, total cholesterol, LDL-cholesterol, and TC/HDL ratio. These effects are consistent with whey addressing multiple components of metabolic syndrome simultaneously through insulin-sensitizing, lipid-lowering, and anti-hypertensive mechanisms.

XOS addresses multiple components of metabolic syndrome including elevated blood glucose, dyslipidemia, and systemic inflammation. Studies in obese high-fat-diet models show XOS reduces body weight, visceral fat, blood lipids, and inflammatory markers. Human data show improvements in T2DM-associated metabolic parameters at 4 g/day.

Animal studies demonstrate yerba mate reverses high-fat diet-induced metabolic syndrome features including insulin resistance, dyslipidemia, and hepatic steatosis. Human observational data in postmenopausal women associate higher YM intake with lower metabolic syndrome components. Dedicated human clinical trials are limited.

Multiple clinical trials and meta-analyses demonstrate that zinc plays a measurable role in metabolic syndrome (MetS), acting on insulin signaling, glycemic control, lipid profiles, and oxidative stress. A 2022 meta-analysis of 13 observational studies (18,073 participants) found higher dietary zinc intake was inversely associated with MetS risk (RR=0.75). Intervention trials show zinc supplementation can improve fasting glucose, insulin resistance (HOMA-IR), and lipid parameters, though effect sizes vary and findings remain somewhat inconsistent across populations.

Beta-sitosterol addresses multiple components of metabolic syndrome—LDL-cholesterol elevation, insulin resistance, and inflammation—in preclinical models. Rodent studies show improvements in lipid profiles, glucose homeostasis, and inflammatory markers simultaneously. No human RCT with metabolic syndrome as a composite primary endpoint has been conducted.

Corn silk polysaccharides are documented to 'inhibit metabolic syndrome' in traditional pharmacological use, and preclinical data show improvements in multiple metabolic syndrome components including blood glucose, obesity, and lipid metabolism. Human clinical RCT evidence addressing metabolic syndrome as a composite endpoint is absent.

Guggul addresses multiple components of metabolic syndrome — dyslipidemia, adiposity, and insulin resistance — through complementary mechanisms. Preclinical studies show guggulsterones inhibit adipocyte differentiation, induce adipocyte apoptosis, and have hypoglycemic effects. Pilot and naturalistic human trials have shown modest lipid and weight effects but lack rigorous controlled data specifically for metabolic syndrome.

T. cordifolia's traditional Ayurvedic designation as a drug that regulates metabolism (Deepana) and its documented activity on blood glucose, triglycerides, cholesterol, and inflammation places it within the metabolic syndrome spectrum. A clinical pilot trial in hypertriglyceridemic patients supports metabolic benefit. Comprehensive metabolic syndrome RCTs are not available.

Tongkat Ali is used traditionally in Southeast Asia for conditions encompassing metabolic syndrome components including diabetes and obesity. Preclinical data show effects on blood glucose, cholesterol, and body fat. Testosterone deficiency — corrected by TA in clinical trials — is an established risk factor for metabolic syndrome. No human trial has specifically enrolled metabolic syndrome patients or assessed MetS diagnostic criteria as endpoints.

MP has been studied in animal models of metabolic syndrome (high-fructose diet), demonstrating reduction of oxidative stress, modulation of NF-κB/Nrf2 pathways, lowering of blood glucose, and hypolipidemic effects. No human trials for metabolic syndrome as a defined endpoint have been conducted. Traditional Ayurvedic use covers the spectrum of 'prameha' conditions overlapping with metabolic syndrome.